Why the study?
With gliflozins reducing cardiovascular death and heart failure hospitalization in patients with heart failure and reduced ejection fraction regardless of diabetes status, practical guidance on cooperation between cardiologists and diabetologists was needed.
Answers are grounded in this paper and cite their sources.
Diabetes mellitus is an important risk factor for the development of heart failure and presence of diabetes significantly worsens heart failure outcome. Introduction of gliflozins to the therapy of heart failure is one of the most important novelty. Gliflozins reduce glucose level by the sodium-glucose contransporter 2 inhibition in proximal tubulus in the kidney. Gliflozins are used as effective antidiabetic drugs with improvement of glycemic control without risk of hypoglycemia, gliflozins decrease blood pressure and patients weight. Recent studies have shown that gliflozins significantly reduce risk of cardiovascular complications and heart failure hospitalizations in diabetic patients. Clinical trials with dapagliflozin and empagliflozin have shown reduction of the risk of cardiovascular death and heart failure hospitalization in the patients with heart failure and reduced ejection fraction both in the patients with diabetes and in the patients without diabetes. The aim of the expert consenzus is to summarize practical aspects in the cooperation of cardiologist and diabetologist in the management of the patients with heart failure and reduced ejection fraction in the context of the current guidelines and other treatment options.
No takes yet. Share an insight, caveat, or question.
Haluzı́k et al. (2021) conducted a review in Chronic heart failure with reduced ejection fraction (HFrEF) with or without type 2 diabetes mellitus. SGLT2 inhibitors (dapagliflozin, empagliflozin) vs. Placebo was evaluated on Composite of cardiovascular death or worsening heart failure (hospitalization or urgent visit) (26% relative risk reduction (dapagliflozin); 25% relative risk reduction (empagliflozin), p=<0.001). Dapagliflozin and empagliflozin reduced the relative risk of cardiovascular death or worsening heart failure by 26% and 25% in patients with HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: